Serum 25-hydroxyvitamin D3 levels affect treatment outcome in pegylated interferon/ribavirin combination therapy for compensated cirrhotic patients with hepatitis C virus genotype 1b and high viral load

被引：10

作者：

Atsukawa, Masanori ^{[1
]}

Tsubota, Akihito ^{[2
]}

Shimada, Noritomo ^{[3
]}

Kondo, Chisa ^{[1
]}

Itokawa, Norio ^{[1
]}

Nakagawa, Ai ^{[1
]}

Hashimoto, Satomi ^{[4
]}

Fukuda, Takeshi ^{[4
]}

Matsushita, Yoko ^{[4
]}

Narahara, Yoshiyuki ^{[4
]}

Iwakiri, Katsuhiko ^{[1
]}

Nakatsuka, Katsuhisa ^{[4
]}

Kawamoto, Chiaki ^{[4
]}

Sakamoto, Choitsu ^{[4
]}

机构：

[1] Chiba Hokusoh Hosp, Nippon Med Sch, Dept Internal Med, Div Gastroenterol, Inzai, Japan

[2] Jikei Univ, Sch Med, ICMR, Kashiwa, Chiba, Japan

[3] Shinmatsudo Cent Gen Hosp, Div Gastroenterol & Hepatol, Matsudo, Chiba, Japan

[4] Nippon Med Sch, Dept Internal Med, Div Gastroenterol & Hepatol, Tokyo 113, Japan

来源：

HEPATOLOGY RESEARCH | 2014年 / 44卷 / 13期

关键词：

cirrhosis; hepatitis C virus; 25-hydroxyvitamin D-3; pegylated interferon; ribavirin; sustained virological response; SUSTAINED VIROLOGICAL RESPONSE; COMMON GENETIC-DETERMINANTS; GENOME-WIDE ASSOCIATION; VITAMIN-D; HEPATOCELLULAR-CARCINOMA; PLUS RIBAVIRIN; PEGINTERFERON ALPHA-2B; NATURAL-HISTORY; SEVERE FIBROSIS; PEG-INTERFERON;

D O I：

10.1111/hepr.12298

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

AimMuch is unknown about the effect of 25-hydroxyvitamin D-3 levels on the outcome of pegylated interferon/ribavirin (PEG IFN/RBV) therapy for hepatitis C virus-related cirrhosis. The purpose of the present study was to analyze and elucidate factors, including 25-hydroxyvitamin D-3, that contribute to a sustained virological response (SVR) in patients with cirrhosis. MethodsWe analyzed whether 25-hydroxyvitamin D-3 contributes to the response to PEG IFN/RBV therapy among 134 cirrhotic patients. ResultsSVR was achieved in 43 patients. The median 25-hydroxyvitamin D-3 level was 20ng/mL. Univariate analysis showed that the following factors contributed to SVR: low-density lipoprotein cholesterol, albumin, 25-hydroxyvitamin D-3, core a.a.70 (a.a.70) substitutions, the number of mutations at the interferon sensitivity-determining region and IL28B genotype. Multivariate analysis identified IL28B genotype and 25-hydroxyvitamin D-3 as independent factors contributing to SVR. Subsequently, SVR rate was examined by using 25-hydroxyvitamin D-3 and other important factors. The SVR rate was 51.8% in patients with core a.a.70 wild and 15ng/mL of 25-hydroxyvitamin D-3, whereas the SVR rate was 7.1% in patients with core a.a.70 wild and <15ng/mL of 25-hydroxyvitamin D-3. The SVR rate was 56.9% in patients with IL28B major genotype and 15ng/mL of 25-hydroxyvitamin D-3. Surprisingly, the SVR rate was 0% in patients with IL28B minor genotype and <15ng/mL of 25-hydroxyvitamin D-3. ConclusionIL28B genotype and 25-hydroxyvitamin D-3 were identified as independent factors contributing to SVR. Stratified analyses according to core a.a.70 substitution and IL28B genotype suggested that 25-hydroxyvitamin D-3 influences the outcome of PEG IFN/RBV therapy for cirrhosis.

引用

页码：1277 / 1285

页数：9

共 47 条

[1] Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b [J].

Abergel, A. ;

Hezode, C. ;

Leroy, V. ;

Barange, K. ;

Bronowicki, J. P. ;

Tran, A. ;

Alric, L. ;

Castera, L. ;

Bernard, P. -H. ;

Henquell, C. ;

Lafeuille, H. ;

Ughetto, S. ;

Darcha, C. ;

Chevallier, M. ;

Martineau, N. ;

Dubost, S. ;

Randl, K. ;

Dhumeaux, D. ;

Bommelaer, G. ;

Bonny, C. .

JOURNAL OF VIRAL HEPATITIS, 2006, 13 (12) :811-820

[2] Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients [J].

Abu-Mouch, Saif ;

Fireman, Zvi ;

Jarchovsky, Jacob ;

Zeina, Abdel-Rauf ;

Assy, Nimer .

WORLD JOURNAL OF GASTROENTEROLOGY, 2011, 17 (47) :5184-5190

[3] Genome-wide association study of circulating vitamin D levels [J].

Ahn, Jiyoung ;

Yu, Kai ;

Stolzenberg-Solomon, Rachael ;

Simon, K. Claire ;

McCullough, Marjorie L. ;

Gallicchio, Lisa ;

Jacobs, Eric J. ;

Ascherio, Alberto ;

Helzlsouer, Kathy ;

Jacobs, Kevin B. ;

Li, Qizhai ;

Weinstein, Stephanie J. ;

Purdue, Mark ;

Virtamo, Jarmo ;

Horst, Ronald ;

Wheeler, William ;

Chanock, Stephen ;

Hunter, David J. ;

Hayes, Richard B. ;

Kraft, Peter ;

Albanes, Demetrius .

HUMAN MOLECULAR GENETICS, 2010, 19 (13) :2739-2745

[4] Effect of Aging on Risk for Hepatocellular Carcinoma in Chronic Hepatitis C Virus Infection [J].

Asahina, Yasuhiro ;

Tsuchiya, Kaoru ;

Tamaki, Nobuharu ;

Hirayama, Itsuko ;

Tanaka, Tomohiro ;

Sato, Mitsuaki ;

Yasui, Yutaka ;

Hosokawa, Takanori ;

Ueda, Ken ;

Kuzuya, Teiji ;

Nakanishi, Hiroyuki ;

Itakura, Jun ;

Takahashi, Yuka ;

Kurosaki, Masayuki ;

Enomoto, Nobuyuki ;

Izumi, Namiki .

HEPATOLOGY, 2010, 52 (02) :518-527

[5] An algorithm for the grading of activity in chronic hepatitis C [J].

Bedossa, P ;

Poynard, T .

HEPATOLOGY, 1996, 24 (02) :289-293

[6] Complementary Role of Vitamin D Deficiency and the Interleukin-28B rs12979860 C/T Polymorphism in Predicting Antiviral Response in Chronic Hepatitis C [J].

Bitetto, Davide ;

Fattovich, Giovanna ;

Fabris, Carlo ;

Ceriani, Elisa ;

Falleti, Edmondo ;

Fornasiere, Ezio ;

Pasino, Michela ;

Ieluzzi, Donatella ;

Cussigh, Annarosa ;

Cmet, Sara ;

Pirisi, Mario ;

Toniutto, Pierluigi .

HEPATOLOGY, 2011, 53 (04) :1118-1126

[7] Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C [J].

Bitetto, Davide ;

Fabris, Carlo ;

Fornasiere, Ezio ;

Pipan, Corrado ;

Fumolo, Elisa ;

Cussigh, Annarosa ;

Bignulin, Sara ;

Cmet, Sara ;

Fontanini, Elisabetta ;

Falleti, Edmondo ;

Martinella, Romina ;

Pirisi, Mario ;

Toniutto, Pierluigi .

TRANSPLANT INTERNATIONAL, 2011, 24 (01) :43-50

[8] Sustained virological response to interferon-α is associated with improved outcome in HCV-related cirrhosis:: A retrospective study [J].

Bruno, Savino ;

Stroffolini, Tommaso ;

Colombo, Massimo ;

Bollani, Simona ;

Benvegnu, Luisa ;

Mazzella, Giuseppe ;

Ascione, Antonio ;

Santantonio, Teresa ;

Piccinino, Felice ;

Andreone, Pietro ;

Mangia, Alessandra ;

Gaeta, Giovanni B. ;

Persico, Marcello ;

Fagiuoli, Stefano ;

Almasio, Piero L. .

HEPATOLOGY, 2007, 45 (03) :579-587

[9] Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis [J].

Bruno, Savino ;

Vierling, John M. ;

Esteban, Rafael ;

Nyberg, Lisa M. ;

Tanno, Hugo ;

Goodman, Zachary ;

Poordad, Fred ;

Bacon, Bruce ;

Gottesdiener, Keith ;

Pedicone, Lisa D. ;

Albrecht, Janice K. ;

Brass, Clifford A. ;

Thompson, Seth ;

Burroughs, Margaret H. .

JOURNAL OF HEPATOLOGY, 2013, 58 (03) :479-487

[10] Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis [J].

Bruno, Savino ;

Shiffman, Mitchell L. ;

Roberts, Stuart K. ;

Gane, Edward J. ;

Messinger, Diethelm ;

Hadziyannis, Stephanos J. ;

Marcellin, Patrick .

HEPATOLOGY, 2010, 51 (02) :388-397

← 1 2 3 4 5 →